Tracking the LKFT expected move helps you see how far Lakefront Biotherapeutics NV ADR's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Lakefront Biotherapeutics NV ADR's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the LKFT expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For LKFT, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The LKFT expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Lakefront Biotherapeutics NV ADR is unlikely to go.
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the LKFT expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Lakefront Biotherapeutics NV ADR expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about LKFT.
